Adult Dosing

Ocular decongestant, astringent

• Instill 1-2 gtt in the affected eye(s) qid

Pediatric Dosing

Ocular decongestant, astringent

• Instill 1-2 gtt in the affected eye(s) qid

• Temporarily relieves ocular redness, burning, or dryness due to minor eye irritations
• To clear mucus build-up from the outer surface of the eye caused by dust, pollen, or smoke
• For use as a protectant against further ocular irritation or for relieving ocular dryness

• Hypersensitivity to any of the ingredients of the product
• Angle-closure glaucoma
• Concomitant use or use within 14 days of discontinuing MAO inhibitors

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Naphazoline component of this combination drug may occasionally cause systemic sympathomimetic effects such as headache, hypertension, cardiac irregularities, nervousness, nausea, dizziness, weakness, and sweating. Drowsiness, decreased body temperature, bradycardia, shock-like hypotension, and coma may occur on overdosage
• Rebound congestion, characterized by reactive hyperemia may occur with prolonged use and may result in overuse of the drug
• Naphazoline component may liberate pigment granules presumably from the iris when used in high doses in elderly patients
• Do not use this combination drug continuously for longer than 2-3 days without consulting a physician as chronic use may damage the blood vessels in the eyes
• Advise patients to discontinue therapy if they experience ocular pain, vision changes, continued ocular redness/irritation, worsening of condition or if their symptoms last >72 hrs
• Advise patients to avoid using contact lenses during treatment period
• Use caution when driving, operating machinery, or performing other hazardous activities as the product may cause temporary vision changes
• Before prescribing this drug, undertake medical history of patients for presence of narrow angle glaucoma
• Do not touch the eyelids or surrounding areas with the dropper tip as this could contaminate the medication and result in serious ocular infections. Replace cap after using
• Overdosage may produce increased ocular redness; pupils may get enlarged temporarily
• On accidental swallowing of this drug, advise patients to seek medical help or immediately contact a Poison Control Center

Cautions: Use cautiously in

• Hypertension
• Cardiovascular disease
• Diabetes mellitus
• Hyperthyroidism
• Infections or injury
• Geriatric patients

Supplemental Patient Information

• Instruct patients wearing soft contact lenses to remove them prior to administration of the drug and to wait at least 15 minutes after instillation
• Instruct patients to avoid use if the drug solution changes color or becomes cloudy
• Instruct patients to store this drug out of reach of children

Pregnancy Category:C

Breastfeeding: Safety unknown. Manufacturer advises nursing mothers to avoid using this combination drug without consulting their clinician.

• EENT: Ongoing or worsening eye redness, eye pain, vision changes, mydriasis, buzzing in ears, burning, transient ocular stinging, blurred vision, ocular irritation, watery eyes, increased lacrimation, elevated IOP, punctate keratitis
• HYPERSENSITIVITY: Allergic reactions including hives, difficulty breathing; swelling of the face, lips, tongue, or throat
• CNS: Dizziness, headache, confusion, anxiety, nervousness, drowsiness, weakness, CNS depression (patients <6 yrs)
• CV: Chest pain, cardiac irregularities, hypertension
• GI: Nausea
• ENDO: Hyperglycemia
• DERM: Sweating

Naphazoline

• Ophthalmic decongestant (sympathomimetic); reduces ocular congestion and redness by stimulating alpha adrenergic receptors
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

Zinc sulfate

• Astringent; relieves irritation
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Clear Eyes ACR

US Availability

Clear Eyes ACR (naphazoline/zinc)

• OTC DROPS: 0.012%/0.25%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Ophthalmic

Decongestant/Astringent Combinations